These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30688170)

  • 21. Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting.
    Kishimoto T; Sanghani S; Russ MJ; Marsh AN; Morris J; Basu S; John M; Kane JM
    Int Clin Psychopharmacol; 2017 May; 32(3):161-168. PubMed ID: 28181959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-acting injectable antipsychotics: evidence of effectiveness and use.
    Manchanda R; Chue P; Malla A; Tibbo P; Roy MA; Williams R; Iyer S; Lutgens D; Banks N
    Can J Psychiatry; 2013 May; 58(5 Suppl 1):5S-13S. PubMed ID: 23945067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between discontinuation due to withdrawal of consent and use of long-acting injectable antipsychotics: A meta-analysis of randomized trials for schizophrenia.
    Kishi T; Sakuma K; Okuya M; Iwata N
    J Psychiatr Res; 2021 Jan; 132():144-150. PubMed ID: 33096355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia.
    Lachaine J; Lapierre ME; Abdalla N; Rouleau A; Stip E
    Can J Psychiatry; 2015 Mar; 60(3 Suppl 2):S40-7. PubMed ID: 25886679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world effectiveness of long-acting injectable vs. oral antipsychotics in patients with bipolar I disorder: a 1-year retrospective observational study.
    Korkmaz ŞA; Gürler S
    Curr Med Res Opin; 2024 May; 40(5):855-861. PubMed ID: 38557295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain.
    Arango C; Baeza I; Bernardo M; Cañas F; de Dios C; Díaz-Marsá M; García-Portilla MP; Gutiérrez-Rojas L; Olivares JM; Rico-Villademoros F; Rodríguez-Jiménez R; Sánchez-Morla EM; Segarra R; Crespo-Facorro B
    Rev Psiquiatr Salud Ment (Engl Ed); 2019; 12(2):92-105. PubMed ID: 29954707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identifying Predictors of Primary Adherence to Second Generation Long-Acting Injectable Antipsychotics Following Discharge from an Acute Inpatient Psychiatry Unit.
    Gilbert JL; Nelson LA; Kriz CR; Liu Y; Iuppa CA; Diefenderfer LA; Elliott ESR; Sommi RW
    Psychopharmacol Bull; 2019 Jun; 49(2):8-16. PubMed ID: 31308578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
    Maestri TJ; Mican LM; Rozea H; Barner JC
    Psychopharmacol Bull; 2018 Mar; 48(3):8-15. PubMed ID: 29713100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study.
    Joo SW; Shon SH; Choi G; Koh M; Cho SW; Lee J
    Eur Neuropsychopharmacol; 2019 Sep; 29(9):1051-1060. PubMed ID: 31362852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges.
    Haddad PM; Correll CU
    Expert Opin Pharmacother; 2023 Mar; 24(4):473-493. PubMed ID: 36919576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rethinking the role of long-acting atypical antipsychotics in the community setting.
    Altamura AC; Aguglia E; Bassi M; Bogetto F; Cappellari L; De Giorgi S; Fagiolini A; Ferrannini L; Girardi P
    Int Clin Psychopharmacol; 2012 Nov; 27(6):336-49. PubMed ID: 22859065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study.
    Agid O; Remington G; Fung C; Nightingale NM; Duclos M; Anger GJ
    Can J Psychiatry; 2022 Mar; 67(3):226-234. PubMed ID: 34792401
    [No Abstract]   [Full Text] [Related]  

  • 33. Barriers to Long-acting Injectable Antipsychotic Adherence During the COVID-19 Pandemic: Observations From One Site.
    Forster SE; Gancz NN; Gaither ML; Haas GL; Starver KD; Steinhauer SR
    J Psychiatr Pract; 2022 Nov; 28(6):497-504. PubMed ID: 36355590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
    Carswell C; Wheeler A; Vanderpyl J; Robinson E
    Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What We Know About Long-acting Injectable Antipsychotics Can Help Innovate HIV Care.
    Kates OS
    AMA J Ethics; 2021 May; 23(5):E405-409. PubMed ID: 34038349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
    Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
    J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
    [No Abstract]   [Full Text] [Related]  

  • 37. Simulated long-term outcomes of early use of long-acting injectable antipsychotics in early schizophrenia.
    Horvitz-Lennon M; Predmore Z; Orr P; Hanson M; Hillestad R; Durkin M; Kim E; Mattke S
    Early Interv Psychiatry; 2019 Dec; 13(6):1357-1365. PubMed ID: 30548103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
    Kishimoto T; Nitta M; Borenstein M; Kane JM; Correll CU
    J Clin Psychiatry; 2013 Oct; 74(10):957-65. PubMed ID: 24229745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Attitudes of European physicians towards the use of long-acting injectable antipsychotics.
    Patel MX; Bent-Ennakhil N; Sapin C; di Nicola S; Loze JY; Nylander AG; Heres S
    BMC Psychiatry; 2020 Mar; 20(1):123. PubMed ID: 32169077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia.
    Cai C; Kozma C; Patel C; Benson C; Yunusa I; Zhao P; Reeder G; Narasimhan M; Bank RL
    J Manag Care Spec Pharm; 2024 Jun; 30(6):549-559. PubMed ID: 38824623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.